Project Grant HT94252510649
Award Date
8/1/25
Completion Date
7/31/29
Dollars Obligated
$880K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
2323 Riverside Dr., Ottawa, ON K1H 1A1, Canada
Similar Awards
The Department of the Army Medical Command awarded a $390,033 Project Grant to Mount Sinai Hospital in Ottawa, Ontario, Canada to identify novel immune evasion tumor immune networks as targets for clear cell renal cell carcinoma immunotherapy. The grant was awarded on August 15, 2022 under the Military Medical Research and Development program (CFDA 12.420) and will support research activities through August 14, 2025. The Military Medical Research and Development program aims to transform...
The University Health Network will receive $611,415 under a three-year Project Grant award from the Department of the Army Medical Command. The grant is part of the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care. Under this award, the University Health Network will conduct research from August 2022 to August 2025 to identify novel immune evasion tumor immune networks...
This $769,073 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research to define and target cancer cell-intrinsic vulnerabilities in renal cell carcinoma. The grant was awarded to the Royal Institution for the Advancement of Learning / McGill Office of Sponsored Research Division, a private university affiliated with McGill University in Montreal, Canada. The research will be conducted from August 1, 2024...
The Defense Health Agency awarded a $416,115 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Research Institute Of The Mcgill University Health Centre. The grant, awarded on August 15, 2024, will fund the development of next-generation prognostic tools for localized clear cell renal cell carcinoma through the integration of genomic, clinical, and pathological features. The award has a performance period ending on August 14, 2026. The Research...
The Department of the Army Medical Command awarded a $116,692 Project Grant to the Royal Institution For The Advancement Of Learning / McGill under the Military Medical Research and Development program. The grant will fund a research project titled "UNDERSTANDING PHYSICAL DETERMINANTS OF HETEROGENEITY IN RENAL CANCER CARCINOMA" from July 15, 2021 to July 14, 2023. The project will be performed at 2323 Riverside Dr., Ottawa, ON K1H 1A1, Canada. Through this funding, the awardee will...
The Defense Health Agency awarded a $464,261 project grant to The Royal Institution For The Advancement Of Learning, a private, non-profit educational institution in Montreal, Canada, to develop the next generation of prognostic tools for localized clear cell renal cell carcinoma. The grant, awarded under the Military Medical Research and Development (CFDA 12.420) program, will fund research to integrate genomic, clinical, and pathological features to create advanced prognostic tools for this...
The Department of the Army Medical Command awarded a $475,457 Project Grant to the Institute of Cancer Research: Royal Cancer Hospital in the United Kingdom. The grant is part of the Military Medical Research and Development program (CFDA 12.420) and will fund research characterizing biomarkers of growth and progression in small renal masses from September 30, 2022 to September 29, 2025. Through this award, the grantee will investigate medical solutions for the battlefield by transforming...
The federal Project Grant award of $1,214,375.00 from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), is funding a research project led by Yale University. The project is investigating the use of decoy-resistant IL-18 and immune checkpoint inhibitors in preclinical murine and ex vivo patient-derived models of renal cell carcinoma. The award began on September 15, 2024 and is set to conclude on September 14, 2028. The Military Medical Research...
The Department of the Army Medical Command awarded Brigham & Women's Hospital Inc. a $130,698 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will support the development of the first targeted therapy for translocation renal cell carcinoma from August 15, 2022 to August 14, 2023. As the parent organization of the awardee, Partners Healthcare System Incorporated will oversee delivery of this innovative medical research effort to develop new...
The Institute For Cancer Research at Temple University received a $187,000 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The two-year award, which runs from April 1, 2021 through March 31, 2023, will support research into therapeutic targeting of P300/CBP in clear cell renal cell carcinoma. The Military Medical Research and Development program aims to transform military and public...